API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
USA (Orange Book)
Europe
0
Canada
0
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
Details:
DOPTELET® (avatrombopag maleate), an oral thrombopoietin receptor agonist, which is indicated for the of thrombocytopenia and for the treatment of severe thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo an invasive procedure.
Lead Product(s): Avatrombopag Maleate
Therapeutic Area: Immunology Product Name: Doptelet
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 06, 2023
Details:
PEGASUS evaluated the efficacy and safety of pegcetacoplan in adult patients with suboptimal response to prior treatment with eculizumab.
Lead Product(s): Avatrombopag Maleate
Therapeutic Area: Immunology Product Name: Doptelet
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2021
Details:
Doptelet is an orally administered thrombopoietin receptor agonist (TPO-RA) that mimics the biologic effects of TPO in stimulating the development and maturation of megakaryocytes, resulting in increased platelet count.
Lead Product(s): Avatrombopag Maleate
Therapeutic Area: Immunology Product Name: Doptelet
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 20, 2021
Details:
Doptelet (avatrombopag) is designed to mimic the biologic effects of thrombopoietin in stimulating the development and maturation of megakaryocytes, resulting in increased platelet count, according to Sobi.
Lead Product(s): Avatrombopag Maleate
Therapeutic Area: Hematology Product Name: Doptelet
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2020
Details:
Though avatrombopag increased platelet counts relative to placebo as expected, the study did not meet the composite primary endpoint of avoiding platelet transfusions, chemotherapy dose reductions by 15 per cent or greater, and chemotherapy dose delays by four days or more.
Lead Product(s): Avatrombopag Maleate
Therapeutic Area: Hematology Product Name: Doptelet
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 09, 2020
Details:
Enrollment remains ongoing for the phase 3 clinical study of avatrombopag for the treatment of patients with CIT.
Lead Product(s): Avatrombopag Maleate
Therapeutic Area: Hematology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 13, 2020